<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport"
          content="width=device-width, height=device-height, initial-scale=1, maximum-scale=1, user-scalable=0, viewport-fit=cover">
    <title>Ultibro - Una vez al dia - Breezhaler</title>
    <link rel="stylesheet" href="style.css">
</head>
<body>
<div class="container">
    <div class="title-container">
        <div class="title">
            ULTIBRO &reg; el producto con evidencia integral<br>
            para el tratamiento de la EPOC
            <!--<img src="assets/title_text.png">-->
            <div class="dots">
                <img src="assets/dots_bg.png">
            </div>
            <div class="shadow"></div>
            <div class="bg"></div>
        </div>
    </div>
    <div class="rueda-container">
        <div class="rueda-scroll">
            <div class="rueda">
                <!-- SVG VA AQUI -->
                <?xml version="1.0" encoding="utf-8"?>
                <img src="assets/logo_rueda.png" class="logo_rueda">
                <div class="the-svg">
                    <svg class="svg" version="1.1" id="rueda" xmlns="http://www.w3.org/2000/svg"
                         xmlns:xlink="http://www.w3.org/1999/xlink"
                         x="0px" y="0px"
                         viewBox="0 0 532.3 531.6" style="enable-background:new 0 0 532.3 531.6;" xml:space="preserve">
            <path class="st0" d="M364.8,44.8"/>
                        <g>
                <circle class="st1" cx="263.4" cy="263.8" r="242.5"/>
                            <circle class="st2" cx="263.4" cy="263.8" r="201.2"/>
                            <path class="st3 trigger i-evidencia-clinica" d="M448.4,74.2c-36.1,40-72.3,80.1-108.4,120.1c-5.2-6.1-14.6-15.6-29.1-22.6c-19.2-9.3-36.8-9.4-45.2-8.9V2
                    c22.2,0.3,56.9,3.4,96.1,18.6C402.9,36.5,431.6,58.9,448.4,74.2z"/>
                            <path class="st4 trigger i-reduccion-costo" d="M531.7,268.2c-0.4,22.9-3.8,58.2-19.4,97.8c-18.1,46-44.4,77.2-61.4,94.5l-114-118.7
                    c7.2-7.5,17.7-20.3,25.1-38.8c5.4-13.6,7.4-25.9,8.1-34.8H531.7z"/>
                            <path class="st5 trigger i-mejor-dispositivo" d="M355.6,512.6c-20.3,7-50.4,14.9-87.6,15.6c-40.1,0.8-72.7-6.9-93.9-13.8c16.7-48.8,33.4-97.6,50.2-146.5
                    c8.8,2.5,22.2,5.3,38.6,4.4c15.3-0.8,27.5-4.3,35.8-7.6C317.6,414.1,336.6,463.4,355.6,512.6z"/>
                            <path class="st6 trigger i-gold" d="M195.9,344.6c-38.3,39.3-76.5,78.6-114.8,118c-17.2-16.9-45.9-49.7-63.8-99.4C3.6,324.8,1.5,290.9,2,268.8
                    h158.2c0,8.7,1.3,24.9,9.8,42.6C178.2,328.4,189.3,339.1,195.9,344.6z"/>
                            <path class="st7 trigger i-costo-efectividad" d="M227.4,171.7c-8.9,4-23.5,11.9-37.2,26.7c-14.2,15.3-21,31.1-24.2,40.4c-51.4-16-102.9-31.8-154.3-47.7
                    c7.2-22.4,23.4-62.9,59.8-101.8c35.5-37.9,73.7-56.7,95.3-65.4C187,73.1,207.2,122.4,227.4,171.7z"/>
                            <circle class="st8" cx="266.1" cy="266.8" r="117.3"/>
                            <text transform="matrix(0.6146 -0.7888 0.7888 0.6146 89.7938 174.4907)" class="st7a st9"><tspan x="0" y="0" class="st8 st10 st11">RELACIÓN DE</tspan>
                                <tspan x="-27.5" y="18" class="st8 st10 st11">COSTO-EFECTIVIDAD</tspan></text>
                            <text transform="matrix(0.9315 0.3636 -0.3636 0.9315 271.1506 60.3772)"
                                  class="st3a st8 st10 st11">EVIDENCIA CLÍNICA</text>
                            <text transform="matrix(0.9315 0.3636 -0.3636 0.9315 275.3068 77.7789)"
                                  class="st3a st8 st10 st11">MAS COMPLETA</text>
                            <text transform="matrix(1 0 0 1 400.5675 309.7235)" class="st4a st9"><tspan x="0" y="0" class="st8 st10 st11">REDUCCIÓN</tspan>
                                <tspan x="0" y="18" class="st8 st10 st11">DE COSTOS</tspan>
                                <tspan x="0" y="36" class="st8 st10 st11">ASOCIADOS</tspan>
                                <tspan x="0" y="54" class="st8 st10 st11">AL MANEJO</tspan>
                                <tspan x="0" y="72" class="st8 st10 st11">DE LA EPOC</tspan></text>
                            <text transform="matrix(1 0 0 1 237.4392 440.6893)" class="st5a st9"><tspan x="0" y="0" class="st8 st10 st11">MEJOR</tspan>
                                <tspan x="-21.3" y="18" class="st8 st10 st11">DISPOSITIVO</tspan>
                                <tspan x="-43.7" y="36" class="st8 st10 st11">PARA INHALACIÓN</tspan></text>
                            <text transform="matrix(1 0 0 1 60.6827 329.9169)" class="st6a st9"><tspan x="0" y="0" class="st8 st10 st12">GOLD</tspan>
                                <tspan x="6.6" y="24" class="st8 st10 st12">2017</tspan></text>
            </g>
            </svg>
                </div>
                <!-- SVG TERMINA AQUI -->

                <div class="info_st3 info i-evidencia-clinica">
                    <img src="assets/info_1.png">
                </div>

                <div class="info_st4 info i-reduccion-costo">
                    <img src="assets/info_2.png">
                </div>

                <div class="info_st6 info i-gold inv">
                    <img src="assets/info_4.png">
                </div>

                <div class="info_st7 info i-costo-efectividad inv">
                    <img src="assets/info_5.png">
                </div>

                <div class="info_st5 info i-mejor-dispositivo">
                    <img src="assets/info_3.png">
                </div>
            </div>
        </div>
    </div>
    <div class="references">
        <div class="reference">
            <b>LABA:</b> Agonista β2 adrenérgico de acción prolongada <br>
            <b>LAMA:</b> Agonista de los receptores muscarínicos de acción prolongada <br>
            <b>ICS:</b> Corticosteroides inhalados <br>
            <b>pMDI:</b> Inhalador presurizado de dosis medida <br>
        </div>
        <div class="reference">
            <b>Referencias:</b><br>
            <b>1.</b> Frampton JE. QVA 149 IND/GLY (indacaterol/glycopyrronium fixed-dose combination): a review of its
            use
            in patients with chronic obstructive pulmonary disease. Drugs. 2014 Mar;74(4):465-88. <br>
            <b>2.</b> Vogelmeier C, Aalamian-Mattheis M, Greulich T, et al S35 Efficacy and safety of the direct switch
            from
            various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd:
            the
            crystal study Thorax 2016;71:A22. (1):140.<br>
            <b>3.</b> Vogelmeier C, Gaga M, Aalamian-Mattheiset M, Greulichal T, Marin J, Castellani W. et al. Efficacy
            and
            safety of direct switch to Indacaterol/ glycopyrronium in patients with moderate COPD: the CRYSTAL
            open-label
            randomised trial. Respir Res. 2017 Jul;18:140.<br>
            <b>4.</b> Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT. et al. Indacaterol-Glycopyrronium
            versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 Jun;374(23):2222-34.<br>
            <b>5.</b> Chan M-C., Tan EC-H & Yang M-C. Cost-effectiveness analysis of a fixed-dose combination of
            indacaterol
            and glycopyrronium as maintenance treatment for COPD. International Journal of Chronic Obstructive Pulmonary
            Disease. 2018;13: 1079-1088.<br>
            <b>6.</b> Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive
            pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur
            Respir J.
            2017;49(2).<br>
            <b>7.</b> Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket guide to COPD diagnosis,
            management, and prevention a guide for health care professionals. 2019 report.<br>
            <b>8.</b> Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G. et al.. The effect of
            indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically
            important
            deterioration in COPD. International journal of chronic obstructive pulmonary disease. 2017
            May;12:1325-1337.
        </div>
    </div>
</div>
<script src="js/rueda.js"></script>
</body>
</html>
